InPheno is dedicated to advancing the discovery and development of new antivirals to fight off major causes of respiratory tract infections. InPheno is offering services in influenza, respiratory syncytial virus (RSV) and parainfluenza viruses (PIV).
Our assays are monitoring the inhibition of plaque formation or of virus-induced cytopathic effects (CPE) by the compounds under study. These assays can also be used to survey the antibody response in vaccinees or to select neutralizing monoclonal antibodies.
InPheno’s assays run with either type A or B influenza reference viruses. A library of ca. 10’000 recent clinical isolates is available for your compound profiling needs.
In addition to assays using live viruses, InPheno is currently developing entry and replicon-based assays for RSV and PIV.